HSBC Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.08M | Buy |
51,637
+21,958
| +74% | +$494K | ﹤0.01% | 1831 |
|
|
2025
Q4 | $663K | Sell |
29,679
-47,206
| -61% | -$1.55M | ﹤0.01% | 2166 |
|
|
2025
Q3 | $2.3M | Sell |
76,885
-20,312
| -21% | -$609K | ﹤0.01% | 1447 |
|
|
2025
Q2 | $3.55M | Buy |
97,197
+45,665
| +89% | +$1.65M | ﹤0.01% | 1280 |
|
|
2025
Q1 | $1.86M | Buy |
51,532
+4,016
| +8% | +$167K | ﹤0.01% | 1484 |
|
|
2024
Q4 | $1.97M | Buy |
47,516
+31,416
| +195% | +$1.56M | ﹤0.01% | 1482 |
|
|
2024
Q3 | $890K | Buy |
+16,100
| New | +$820K | ﹤0.01% | 1754 |
|
|
2024
Q2 | – | Sell |
-17,349
| Closed | -$810K | – | 3128 |
|
|
2024
Q1 | $810K | Sell |
17,349
-2,114
| -11% | -$99.7K | ﹤0.01% | 1872 |
|
|
2023
Q4 | $931K | Sell |
19,463
-7,512
| -28% | -$291K | ﹤0.01% | 1799 |
|
|
2023
Q3 | $958K | Buy |
26,975
+2,662
| +11% | +$105K | ﹤0.01% | 1738 |
|
|
2023
Q2 | $1.13M | Sell |
24,313
-2,699
| -10% | -$125K | ﹤0.01% | 1659 |
|
|
2023
Q1 | $1.08M | Sell |
27,012
-45,468
| -63% | -$1.95M | ﹤0.01% | 1721 |
|
|
2022
Q4 | $3.28M | Buy |
72,480
+61,631
| +568% | +$2.42M | ﹤0.01% | 1472 |
|
|
2022
Q3 | $457K | Sell |
10,849
-2,884
| -21% | -$148K | ﹤0.01% | 2215 |
|
|
2022
Q2 | $810K | Sell |
13,733
-935
| -6% | -$57.5K | ﹤0.01% | 2043 |
|
|
2022
Q1 | $1.07M | Buy |
14,668
+8,231
| +128% | +$573K | ﹤0.01% | 1902 |
|
|
2021
Q4 | $547K | Sell |
6,437
-397
| -6% | -$32.3K | ﹤0.01% | 2406 |
|
|
2021
Q3 | $611K | Sell |
6,834
-1,838
| -21% | -$166K | ﹤0.01% | 2137 |
|
|
2021
Q2 | $833K | Buy |
8,672
+4,463
| +106% | +$465K | ﹤0.01% | 1864 |
|
|
2021
Q1 | $480K | Sell |
4,209
-5,753
| -58% | -$783K | ﹤0.01% | 1991 |
|
|
2020
Q4 | $1.4M | Buy |
9,962
+4,699
| +89% | +$557K | ﹤0.01% | 1496 |
|
|
2020
Q3 | $445K | Buy |
+5,263
| New | +$436K | ﹤0.01% | 2020 |
|
|
2020
Q1 | – | Sell |
-25,424
| Closed | -$1.1M | – | 2970 |
|
|
2019
Q4 | $1.1M | Sell |
25,424
-3,024
| -11% | -$125K | ﹤0.01% | 1787 |
|
|
2019
Q3 | $1.22M | Buy |
+28,448
| New | +$1.55M | ﹤0.01% | 1851 |
|
|
2018
Q2 | – | Sell |
-4,167
| Closed | -$213K | – | 2682 |
|
|
2018
Q1 | $213K | Buy |
+4,167
| New | +$210K | ﹤0.01% | 2373 |
|
|
2017
Q1 | – | Sell |
-8,645
| Closed | -$607K | – | 2489 |
|
|
2016
Q4 | $607K | Buy |
+8,645
| New | +$613K | ﹤0.01% | 1687 |
|
|
2015
Q3 | – | Sell |
-2,141
| Closed | -$219K | – | 2122 |
|
|
2015
Q2 | $219K | Buy |
+2,141
| New | +$166K | ﹤0.01% | 1782 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
HSBC Holdings's RARE Position: Q1 2026 in Review
HSBC Holdings increased its Ultragenyx Pharmaceutical (RARE) stake by 74% in Q1 2026, buying an estimated $494K and bringing the position to 51,637 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1831.
HSBC Holdings first reported a position in RARE in Q2 2015 and has held it in 27 quarters since. The position peaked at $3.55M in Q2 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- HSBC Holdings held 51,637 shares of Ultragenyx Pharmaceutical worth $1.08M as of Q1 2026.
- HSBC Holdings bought 21,958 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $494K.
- Ultragenyx Pharmaceutical made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1831 holding.
- HSBC Holdings first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 27 quarters since.
- HSBC Holdings's Ultragenyx Pharmaceutical position peaked at $3.55M in Q2 2025.
- 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.